前立腺肥大症患者に対するナフトピジル75 mg の有効性および安全性に関する検討
スポンサーリンク
概要
- 論文の詳細を見る
We investigated the clinical efficacy and safety of administration of naftopidil at 75 mg for clinically benign hyperplasia patients who had moderate or severe urinary disturbance according to guidelines for clinical studies regarding urination disorder. Among patients with benign prostatic hyperplasia who were treated with a a1-adrenoceptor blocker, we administered naftopidil (75 mg/day) for 12 weeks to 85 patients in whom the global severity was evaluated as moderate or severe. This agent significantly reduced the international prostate symptom score (I-PSS) and residual urine volume, and improved the QOL index and maximum urine flow volume in comparison with the baselines. Concerning the global treatment response, a partial response or better was achieved in 83.8% of the patients. Neither blood pressure nor heart rate were changed in patients who continued to receive this therapy. Side effects included orthostatic hypotension (1 patient : discontinuation), dizziness (2 patients : discontinuation, 1 patient : continuation), and palpitation (1 patient : discontinuation). These results suggest that a once-a-day administration of naftopidil at 75 mg safely relieves urination/accumulated urine symptoms in patients with moderate or severe urination disorder related to prostatic hypertrophy.
論文 | ランダム
- 粉体プロセス計測へのトモグラフィの応用 (粉体プロセスのオンライン計測)
- 長期透析患者が抱える不安やストレスの表出に影響を及ぼす要因の分析
- 2輪車用ステアリングダンパー・アルミニウム中空鍛造技術
- 路面反力のフィードバックによる2輪駆動型移動マニピュレータの安定化制御
- 非ホロノミック2輪車両系に対するカスケードフォーメーション制御